éù MRI åéù Contrast-enhanced MRI, ëùîæøé÷éí çåîøé ðéâåã.
ìà òåùéí contrast enhanced áìé öåøê îéåçã (áã"ë îçìåú îåç, äú÷ôé ìá åñåâé ñøèï ìîéðéäí - ëùøåöéí ì÷áì úîåðä èåáä ùì ëìé äãí å\àå äìéîôä).
ëîå ëï, äöéèåè äáà àåîø ù-FDA äúéçñ ìæä åìà îöà ñéáä ìäçùéá àú äùàøéåú äàìä ëîæé÷åú ìáøéàåú:
ìîøåú ù-FDA âí äåöéàå äîìöä ìà ìäùúîù áçåîøé äðéâåã á-MRI ììà öåøê îîùé.Just last month, the FDA similarly concluded that there are no adverse health effects from gadolinium retained in the brain after contrast MRI, so restricting use of the agent is not warranted. But the agency said it would have a public meeting on the issue in the future.
öéèåè ääåãòä áúâåáä